

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AYLA PHARMA LLC,
Petitioner

v.

NOVARTIS AG,
Patent Owner.

U.S. Patent No. 9,533,053 to Gamache *et al.*

Issue Date: January 3, 2017

Title: High Concentration Olopatadine Ophthalmic Composition

Inter Partes Review No.: IPR2020-00295

**PETITIONER'S REPLY TO PATENT OWNER'S
PRELIMINARY RESPONSE**

Mail Stop "PATENT BOARD"

Patent Trial and Appeal Board

U.S. Patent and Trademark Office

P.O. Box 1450

Alexandria, VA 22313-1450

TABLE OF CONTENTS

	<u>Page</u>
I. INSTITUTION SHOULD NOT BE DENIED BASED ON § 325(D).....	1
A. Petitioner’s Asserted Grounds Were Not Considered During Prosecution (<i>Becton</i> Factors (a-d)).....	1
B. Additional Evidence and Facts Presented in the Petition Warrant Reconsideration (<i>Becton</i> Factor (f))	3
C. The Examiner Erred in Its Evaluation of the Asserted Prior Art (<i>Becton</i> Factor (e)).....	4
II. THE <i>APPLE</i> FACTORS DO NOT SUPPORT DENIAL OF INSTITUTION UNDER § 314(A).....	6
A. <i>Apple</i> Factors 1 & 2	7
B. <i>Apple</i> Factor 3.....	7
C. <i>Apple</i> Factors 4 & 5	9
D. <i>Apple</i> Factor 6.....	11
III. CONCLUSION	12

TABLE OF AUTHORITIES

	Page(s)
Cases	
<i>Apotex v. UCB Biopharma</i> , IPR2019-00400, Paper 17, 24 (July 15, 2019).....	1, 12
<i>Apple Inc. v. Fintiv, Inc.</i> IPR2020-00019 Paper 11 (PTAB March 20, 2020).....	passum
<i>Apple v. Omni Medsci</i> , IPR2020-00029, Paper 7, 55 (April 22, 2020).....	5, 7, 11
<i>Artic Cat v. Polaris Indus.</i> , IPR2017-00433, Paper 17, 19 (July 5, 2017)	12
<i>Clim-A-Tech v. Ebert</i> , IPR2017-01863, Paper 13, 18	2
<i>Ex parte Ditzik</i> , 2018-000087, 6 (PTAB Mar. 2, 2018)	10
<i>Ethicon v. Quigg</i> , 849 F.2d 1422 (Fed. Cir. 1988).....	6
<i>Gen. Plastic Indus. Co. v. Canon Kabushiki Kaisha</i> , IPR2016-01357, Paper 19 (PTAB Sept. 6, 2017).....	8, 9
<i>Hyperbranched Medical Tech. v. Confluent Surgical</i> , IPR2018-01097, Paper 14, 24 (PTAB Nov. 14, 2018)	1
<i>Lowe’s. v. Nichia</i> , IPR2017-02011, Paper 13, 18 (Mar. 12, 2018).....	12
<i>Meitzner v. Mindick</i> , 549 F.2d 775 (CCPA 1977)	11
<i>Mylan Pharmaceuticals Inc. v. Almirall, LLC</i> . IPR2019-01095, Paper 12 (PTAB Nov. 27, 2019)	9

<i>Mylan Pharms. Inc. v. Merck Sharp & Dohme Corp.</i> , IPR2020-00040, Paper 21 (PTAB May 12, 2020).....	4, 8, 9, 11
<i>NHK Spring Co., Ltd. v. Intri-Plex Techs.</i> Case IPR2018-00752, Paper 8 (Sept. 12, 2018)	6
<i>Novartis AG v. Noven Pharm. Inc.</i> , 853 F.3d 1289 (Fed. Cir. 2017).....	6
<i>Petroleum Geo-Servs. v. W. Geco</i> , IPR2014-01477, Paper 18, 32 (March 17, 2015).....	12
<i>Steadymed LTD. v. United Therapeutics Corp.</i> , IPR 2016-00006.....	9
<i>TRW Automotive v. Magna Elecs.</i> , IPR2014-00261, Paper 19, 12 (June 26, 2014).....	1
<i>Valve Corp. v. Elec. Scripting Prods., Inc.</i> , IPR2019-00064, Paper 10 (May 1, 2019).....	8
<i>ZTE v. Bell Northern Research</i> , IPR2019-01365, Paper 13 (PTAB Feb. 11, 2020)	5

...

I. INSTITUTION SHOULD NOT BE DENIED BASED ON § 325(D)
A. Petitioner’s Asserted Grounds Were Not Considered During Prosecution (*Becton* Factors (a-d))

There is no dispute that the Examiner never put forth **any** prior art rejection during the prosecution of the ’053 patent, including the grounds advanced in the Petition and supporting declarations. The crux of Novartis’ argument under § 325(d) is: (1) the Examiner “considered” Argentum’s IPR petition to the ’154 patent because it was disclosed in an IDS during prosecution of the ’053 patent, and (2) the Examiner issued a *Schneider*-based rejection during the prosecution of the related ’154 patent. POPR at 31. These arguments fail for several reasons.

First, Novartis presumes that its mere disclosure, in an IDS, of the *Argentum* IPR petition and/or the other prior art references, meant that the Examiner considered and relied on them. Presumptive awareness, however, is not enough for a § 325(d) denial. *TRW Automotive v. Magna Elecs.*, IPR2014-00261, Paper 19, 12 (June 26, 2014). “The Board has consistently declined to exercise its discretion under § 325(d) based on the mere citation of references in an IDS that were not applied by the Examiner.” *Apotex v. UCB Biopharma*, IPR2019-00400, Paper 17, 24 (July 15, 2019); Petition, 12 (citing cases). Where, as here, the prior art is “simply being of record, but not applied in any rejection by the Examiner during examination ... provides little impetus for [the PTAB] to exercise [its] discretion to deny institution under § 325(d).” *Hyperbranched Medical Tech. v. Confluent*

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.